Phase III Trial Oversight Should Rely On Adverse Event "Summaries," CRO Association Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The Association of Clinical Research Organizations supports using partially blinded data summaries to help institutional review boards overseeing multi-center trials
You may also be interested in...
Adverse Events Definition Should Be Narrower, IRB Groups Tell FDA
The Consortium of Independent Review Boards favors reporting only adverse events that "probably or definitely" related to the study drug. Current regulation requires adverse events to be reported to IRBs if they are "at least possibly" related to the drug.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.